Results of the Czech National Colorectal Cancer Screening Programme – Faecal Occult Blood Tests

Česká verzia

Authors: B. Seifert ¹; O. Májek ^2,3; M. Zavoral ⁴; N. Král ¹; Š. Suchánek ⁴; O. Ngo ²; L. Dušek ^2,3
Authors place of work: Ústav všeobecného lékařství, 1. LF UK v Praze ¹; Institut bio statistiky a analýz, LF a PřF MU, Brno ²; Ústav zdravotnických informací a statistiky ČR, Praha ³; Interní klinika 1. LF UK a ÚVN Praha ⁴
Published in the journal: Klin Onkol 2014; 27(Supplementum 2): 87-97
doi: https://doi.org/10.14735/amko20142S87

Summary

Introduction:
The nationwide Colorectal Cancer Screening Programme was introduced in the Czech Republic in 2000. The aim of this article is to describe the employment of faecal occult blood tests (FOBTs) by the Czech population within the screening programme, and to provide information on the latest results of the programme.

Material and Methods:
Data on the development of the colorectal cancer (CRC) burden in the Czech population is obtained from the Czech National Cancer Registry, a database required by the Czech law that has been collecting comprehensive data on cancer patients since 1977. Data on FOBT employment can be obtained from health care payers, and was provided by the Czech National Reference Centre. Results: Around 8,000 patients are diagnosed with colorectal cancer in the Czech Republic each year, and the number of CRC deaths is about 4,000. Despite the ongoing screening programme, significant improvements in the proportional representation of cancer stages (i.e., improvements in early detection of CRC cases) have yet to be seen. Although the number of FOBTs performed in the Czech Republic has significantly grown in the long term (which is accompanied by an increase in coverage by this screening test), the total coverage of the Czech population aged over 50 was only 25.5% in 2012. The Olomouc Region, the Zlin region, and the Usti nad Labem region had the highest coverage rates by CRC screening based on FOBT (over 28%), while the Capital of Prague had the lowest coverage rate (18%). Since 2008, FOBT positivity rates have seen a continuous and significant increase, reaching 6.9% in 2012. Between 13 to 14% of FOBTs in women are performed by practical gynaecologists.

Conclusion:
Despite a significant increase in the participation rate in recent years, which was partially improved by the involvement of practical gynaecologists, the programme unfortunately still covers only a quarter of the eligible population. Implementation of effective measures aimed at getting people interested in preventive examinations (including the recently introduced programme of personalized invitations) is therefore essential; otherwise, the screening programme will not be successful on the population level.

Key words:
colorectal neoplasms – mass screening – occult blood – primary health care

This study was supported by the project 36/14//NAP “Development and implementation of methodology for the evaluation of effectiveness of personalised invitations of citizens to cancer screening programmes” as part of the programme of the Czech Ministry of Health “National action plans and conceptions”.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
18. 9. 2014

Accepted:
30. 10. 2014

Zdroje

1. The Council of the European Union. Council Recommendation of 2 December 2003 on cancer screening (2003/ 878/ EC). Off J Eur Union 2003; L 327: 34– 38.

2. Zavoral M, Suchanek S, Zavada F et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009; 15(47): 5907– 5915.

3. Majek O, Gondos A, Jansen L et al. Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer 2012; 106(11): 1875– 1880.

4. Zavoral M, Suchanek S, Majek O et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol 2014; 20(14): 3825– 3834. doi: 10.3748/ wjg.v20.i14.3825.

5. Karsa L, Anttila A, Ronco G et al (eds). Cancer screening in the European Union: report on the implementation of the Council Recommendation on cancer screening. Luxembourg: European Communities 2008.

6. Greegor DH. Occult blood testing for detection of asymptomatic colon cancer. Cancer 1971; 28(1): 131– 134.

7. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328(19): 1365– 1371.

8. Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal‑ occult‑blood screening for colorectal cancer. Lancet 1996; 348(9040): 1472– 1477.

9. Kronborg O, Fenger C, Olsen J et al. Randomised study of screening for colorectal cancer with faecal‑ occult‑blood test. Lancet 1996; 348(9040): 1467– 1471.

10. Hewitson P, Glasziou P, Watson E et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008; 103(6): 1541– 1549. doi: 10.1111/ j.1572‑ 0241.2008.01875.x.

11. Segnan N, Patnick J, von Karsa L (eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: Publications Office of the European Union 2010.

12. van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135(1): 82– 90. doi: 10.1053/ j.gastro.2008.03.040.

13. Segnan N, Patnick J, Karsa L (eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. Luxembourg: Publications Office of the European Union 2010.

14. Dušek L, Mužík J, Kubásek M et al (eds). Epidemiologie zhoubných nádorů v České republice [Internet]. Brno: Masarykova univerzita 2005 [citováno 30. srpna 2014]. Dostupný z: http:/ / www.svod.cz.

15. dos Santos Silva I (ed). Cancer epidemiology: principles and methods. Lyon: IARC press 1999.

16. Pavlik T, Majek O, Buchler T et al. Trends in stage‑ specific population‑based survival of cancer patients in the Czech Republic in the period 2000– 2008. Cancer Epidemiol 2014; 38(1): 28– 34. doi: 10.1016/ j.canep.2013.11.002.

17. Mandel JS, Church TR, Bond JH et al. The effect of fecal occult‑blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343(22): 1603– 1607.

18. Vainio H, Bianchini F (eds). Breast cancer screening. Lyon: IARC Press 2002.

19. Moss S, Ancelle‑ Park R, Brenner H. Evaluation and interpretation of screening outcomes. In: Segnan N, Patnick J, Karsa L (eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. Luxembourg: Publications Office of the European Union 2010.

20. Jepson R, Clegg A, Forbes C et al. The determinants of screening uptake and interventions for increasing uptake: a systematic review. Health Technol Assess 2000; 4(14): 1– 133.

21. Malila N, Oivanen T, Malminiemi O et al. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. BMJ 2008; 337: a2261. doi: 10.1136/ bmj.a2261.

22. Steele RJ, McClements PL, Libby G et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009; 58(4): 530– 535. doi: 10.1136/ gut.2008.162883.

23. Hol L, van Leerdam ME, van Ballegooijen M et al. Screening for colorectal cancer: randomised trial comparing guaiac‑based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59(1): 62– 68. doi: 10.1136/ gut.2009.177089.